ReviewCureus2025
Statin Therapy as a Preventive Strategy for Nephrolithiasis: A Review of Current Evidence.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent nephrolithiasis remains a significant clinical challenge due to the highly variable and multifactorial etiology of kidney stone formation, which complicates the development of effective preventive strategies. Statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, are among the most widely prescribed medications, primarily for their cholesterol-lowering effects. Beyond their lipid-lowering properties, statins exhibit pleiotropic effects, including anti-inflammatory and antioxidative actions, that may contribute to reducing kidney stone formation. Moreover, statins are widely available, well-tolerated, and safe, highlighting them as a promising therapeutic option for nephrolithiasis prevention. Preclinical studies and observational data suggest that statins could play a role in preventing recurrent kidney stones. Despite encouraging preliminary findings, however, clinical evidence supporting the efficacy of statins in kidney stone prevention is currently limited. This review explores the potential mechanisms, preclinical findings, and current evidence regarding the use of statins as an adjunct therapy for recurrent nephrolithiasis and discusses the need for prospective clinical trials to investigate the efficacy of this therapy. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.